Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?
Therapy (Target) Indication Status (2025) Current Ownership TECELRA(afamitresgene, targets MAGE-A4) Synovial sarcoma (unresectable/metastatic) FDA approved Aug 2024 Biospace; ~16 patients treated in launch year Nasdaq. Sold to US WorldMeds (2025) Adaptimmune Letetresgene (lete-cel, NY-ESO-1) MRCLS and synovial sarcoma (advanced solid tumors) Phase II completed (42% response rate) Stocktitan; FDA Breakthroughdesignation in 2025 Stocktitan; BLA filing planned for 2025. Sold to US WorldMeds (2025) Adaptimmune Uzatresegene…